Endocrinology & Metabolism Clinical Trials

Statistical methods in endocrinology & metabolism trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All endocrinology & metabolism trials

698 results

• An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD): Complete Statistical AnalysisIndependent statistical analysis of An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD): primary endpoint results, effect estimate with…Phase 4Results postedn = 78NCT01806298
• An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia: Complete Statistical AnalysisIndependent statistical analysis of An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 315NCT01078675
• An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge): Complete Statistical AnalysisIndependent statistical analysis of An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 47NCT03789656
• anaGOIndependent statistical analysis of A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 165NCT03002974
• Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women: Complete Statistical AnalysisIndependent statistical analysis of Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 23NCT01889199
• Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1: Complete Statistical AnalysisIndependent statistical analysis of Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02574910).Phase 1Results postedn = 4NCT02574910
• ANDROMEDA-SHOCKIndependent statistical analysis of the ANDROMEDA-SHOCK randomized trial comparing peripheral perfusion versus lactate targeted fluid resuscitation in septic shock, including trial design, endpoints, statistical methodology, and interpretation.Phase NAn = 46NCT03762005
• Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02597101).Phase 2Results postedn = 14NCT02597101
• Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker: Complete Statistical AnalysisIndependent statistical analysis of Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 80NCT04408586
• Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00288366).Phase NAResults postedn = 49NCT00288366
• Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer: Complete Statistical AnalysisIndependent statistical analysis of Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 6NCT00003453
• Apelin Levels and G212A Polymorphism of Apelin Receptor (APJ): Complete Statistical AnalysisIndependent statistical analysis of Apelin Levels and G212A Polymorphism of Apelin Receptor (APJ): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01121172).Phase NAResults postedn = 180NCT01121172
• APOGEEIndependent statistical analysis of Feasibility Study on the Contribution of Guided Puncture With Echoendoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01892501).Phase NAResults postedn = 75NCT01892501
• APPLEIndependent statistical analysis of Arthritis Pilot for Preserving Muscle While Losing Weight: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02239939).Phase NAResults postedn = 37NCT02239939
• APPRISE 1Independent statistical analysis of Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 3NCT00613730
• APROPOSIndependent statistical analysis of A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01907269).Phase NAResults postedn = 2,684NCT01907269
• AQUACEL® Ag+ Extra™ and Cutimed™ Sorbact® Dressing in the Management of Venous Leg Ulcers Over a 12-week Period: Complete Statistical AnalysisIndependent statistical analysis of AQUACEL® Ag+ Extra™ and Cutimed™ Sorbact® Dressing in the Management of Venous Leg Ulcers Over a 12-week Period: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 203NCT05892341
• ARBIndependent statistical analysis of Angiotensin II Blockade and Inflammation in Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01684748).Phase 4Results postedn = 20NCT01684748
• Arimoclomol in Amyotropic Lateral Sclerosis – Open Label Extension Trial: Complete Statistical AnalysisIndependent statistical analysis of Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03836716).Phase 3Results postedn = 120NCT03836716
• Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients: Complete Statistical AnalysisIndependent statistical analysis of Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 67NCT02478580
• Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I: Complete Statistical AnalysisIndependent statistical analysis of Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 1/2Results postedn = 3NCT02702115
• Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II: Complete Statistical AnalysisIndependent statistical analysis of Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 1/2Results postedn = 9NCT03041324
• ASPIREIndependent statistical analysis of Coaching Veterans to Healthy Weights and Wellness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00967668).Phase NAResults postedn = 481NCT00967668
• Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca: Complete Statistical AnalysisIndependent statistical analysis of Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 11NCT01555489
• Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2/3Results postedn = 48NCT01997411
• Assessment of KAN-101 in Celiac Disease (ACeD): Complete Statistical AnalysisIndependent statistical analysis of Assessment of KAN-101 in Celiac Disease (ACeD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04248855).Phase 1Results postedn = 41NCT04248855
• Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE): Complete Statistical AnalysisIndependent statistical analysis of Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 1,462NCT03067441
• Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00826007).Phase NAResults postedn = 587NCT00826007
• ASSUREIndependent statistical analysis of Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 49NCT02750501
• AstellasIndependent statistical analysis of A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 30NCT01265537
• ATTAIN-1Complete statistical analysis of ATTAIN-1, a randomized phase 3 trial of orforglipron in adults with obesity or overweight with weight-related comorbidities, including its mixed-effects methodology, primary weight endpoint, secondary metabolic outcomes, safety,…Phase 3Results postedn = 3,127NCT05869903
• ATTRibute-CMIndependent statistical analysis of Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 632NCT03860935
• Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase EARLY_1Results postedn = 24NCT02726542
• Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 41NCT01849783
• Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009): Complete Statistical AnalysisIndependent statistical analysis of Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer…Phase 1Results postedn = 12NCT00562640
• Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 16NCT03610490
• AVALLIndependent statistical analysis of Assessment of an School-based Intervention in Eating Habits and Physical Activity in Schoolchildren: the AVall Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 509NCT01156805
• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100): Complete Statistical AnalysisIndependent statistical analysis of Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 998NCT02718417
• AWARD-2Independent statistical analysis of A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01075282).Phase 3Results postedn = 810NCT01075282
• AWARD-6Independent statistical analysis of the randomized phase 3 AWARD-6 trial comparing dulaglutide with liraglutide in type 2 diabetes, including the HbA1c non-inferiority analysis, secondary endpoints, statistical methods, safety, and interpretation.Phase 3Results postedn = 599NCT01624259
• AWARD-CHN3Independent statistical analysis of A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 291NCT04591626
• AWARD-JPNIndependent statistical analysis of A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 591NCT04809220
• AWARD-PEDSIndependent statistical analysis of A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 154NCT02963766
• Azacitidine and Pembrolizumab in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and Pembrolizumab in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03264404).Phase 2Results postedn = 36NCT03264404
• BARIIndependent statistical analysis of the Bypass Angioplasty Revascularization Investigation (BARI), a randomized phase 3 trial comparing percutaneous coronary angioplasty and coronary artery bypass in cardiovascular and coronary disease.Phase 3NCT00000462
• BCC-RAD-13Independent statistical analysis of Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 5NCT02128100
• BEAGLE R21Independent statistical analysis of Behavioral Economics Applications to Geriatrics Leveraging EHRs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03704389).Phase NAResults postedn = 664NCT03704389
• BEGIN™Independent statistical analysis of Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 1,030NCT00982644
• BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 1,006NCT00972283
• BEGIN™Independent statistical analysis of Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 460NCT01068678

← All therapeutic areas